Cetuximab and Radiotherapy for HPV-Associated Oropharynx Cancer

Cetuximab and Radiotherapy for HPV-Associated Oropharynx Cancer Name of a Trial Phase III Randomized Study of Radiotherapy with Cisplatin or Cetuximab in Patients with Human Papilloma Virus-Associated Oropharyngeal Cancer (RTOG-1016). See a custom summary. Principal Investigators Dr. Andy Trotti, Radiation Therapy Oncology Group Dr. Maura Gillison, Ohio State University Drs. Andy M. Trotti and Maura … Continue reading “Cetuximab and Radiotherapy for HPV-Associated Oropharynx Cancer”

Cetuximab and Radiotherapy for HPV-Associated Oropharynx Cancer

Name of a Trial

Phase III Randomized Study of Radiotherapy with Cisplatin or Cetuximab in Patients with Human Papilloma Virus-Associated Oropharyngeal Cancer (RTOG-1016). See a custom summary.

Principal Investigators

Dr. Andy Trotti, Radiation Therapy Oncology Group

Dr. Maura Gillison, Ohio State University

Drs. Andy M. Trotti and Maura Gillison
Principal Investigators

Why This Trial Is Important

Oropharyngeal squamous dungeon carcinoma (OSCC) is a form of conduct and neck cancer that forms in a center partial of a throat, that includes a bottom of a tongue, a tonsils, and a soothing palate. Although OSCC was once suspicion to be a singular disease, new investigate has suggested that it has dual graphic types: cancers that exam certain for tellurian papillomavirus (HPV) and those that are HPV-negative.

Oropharyngeal tumors disastrous for HPV have been associated to tobacco and ethanol abuse, since HPV-positive malignancies might be associated to passionate behavior. Patients with HPV-associated OSCC are expected to be younger during a time of diagnosis and have a softened augury than those with HPV-negative malignancies. In contrariety with a rates of other verbal cancers, that have depressed as smoking rates have declined, a occurrence of HPV-positive OSCC is on a rise.

Current diagnosis strategies for oropharyngeal cancer are formed on growth stage, rather than HPV status, and include of medicine or deviation with or though cisplatin-based chemotherapy. Cancer response rates following cisplatin-based chemotherapy and radiotherapy are generally good, though studies have shown that this multiple diagnosis proceed dramatically increases poisonous side effects. Since some-more than 80 percent of patients with HPV-positive tumors tarry during slightest 5 years after diagnosis, these patients might do only as good on a less-toxic regimen.

One study questioning a multiple of cetuximab, a monoclonal antibody destined opposite a protein called EGFR, and radiotherapy in conduct and neck cancer demonstrated softened studious presence compared with deviation alone. The use of this multiple increasing skin irritation, though differently it had a same side effects as radiotherapy alone. An analysis of patients in this hearing suggested that those with OSCC who were masculine and younger, a organisation that mirrors a HPV-positive population, benefited many from a multiple therapy. These formula suggested that deviation and cetuximab, instead of cisplatin-based chemotherapy, might revoke diagnosis toxicity though compromising cancer control for patients with HPV-positive OSCC.

In this clinical trial, patients with HPV-positive OSCC will be incidentally reserved to accept cisplatin chemotherapy and intensity-modulated deviation therapy (IMRT) or cetuximab and IMRT. Prior to treatment, patients will finish a computer-administered consult on conduct and neck cancer risk factors, including tobacco exposure, ethanol use, and verbal hygiene. During and after treatment, patients will also news a poisonous side effects they experience. Clinicians will guard a patients for growth response, toxicity, peculiarity of life, progression-free survival, and altogether survival.

“This is a initial randomized proviso III hearing specific to a HPV-positive studious population,” pronounced Dr. Gillison. “There are a lot of peculiarity of life outcomes incorporated [into a trial] about both strident toxicity and long-term toxicity, and a patients are stating their toxicity knowledge directly on things like nausea, vomiting, ability to swallow, pain, and appetite turn regulating touch-screen surveys.

“It also includes things that we have never looked during before, that will concede us to do a cost-effectiveness analysis. The initial intensity outcome is that one of a treatments is softened than a other. Then we get an answer in terms of illness control. If a dual treatments are equivalent, afterwards we see that one gives a studious a best peculiarity of life. There is also a probability that they are equal and one of them has a cost-benefit to multitude over a other,” Dr. Gillison added.

For More Information

See a lists of entrance criteria and hearing hit information or call a NCI’s Cancer Information Service during 1-800-4-CANCER (1-800-422-6237). The toll-free call is confidential.

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply